Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut.
Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut
Drug Metab Dispos. 2023 Jun;51(6):672-684. doi: 10.1124/dmd.122.001007. Epub 2023 Mar 27.
Significant interindividual and intraindividual variations on cytochrome P450 (CYP)-mediated drug metabolism exist in the general population globally. Genetic polymorphisms are one of the major contribution factors for interindividual variations, but epigenetic mechanisms mainly contribute to intraindividual variations, including DNA methylation, histone modifications, microRNAs, and long non-coding RNAs. The current review provides analysis of advanced knowledge in the last decade on contributions of epigenetic mechanisms to intraindividual variations on CYP-mediated drug metabolism in several situations, including (1) ontogeny, the developmental changes of CYP expression in individuals from neonates to adults; (2) increased activities of CYP enzymes induced by drug treatment; (3) increased activities of CYP enzymes in adult ages induced by drug treatment at neonate ages; and (4) decreased activities of CYP enzymes in individuals with drug-induced liver injury (DILI). Furthermore, current challenges, knowledge gaps, and future perspective of the epigenetic mechanisms in development of CYP pharmacoepigenetics are discussed. In conclusion, epigenetic mechanisms have been proven to contribute to intraindividual variations of drug metabolism mediated by CYP enzymes in age development, drug induction, and DILI conditions. The knowledge has helped understanding how intraindividual variation are generated. Future studies are needed to develop CYP-based pharmacoepigenetics to guide clinical applications for precision medicine with improved therapeutic efficacy and reduced risk of adverse drug reactions and toxicity. SIGNIFICANCE STATEMENT: Understanding epigenetic mechanisms in contribution to intraindividual variations of CYP-mediated drug metabolism may help to develop CYP-based pharmacoepigenetics for precision medicine to improve therapeutic efficacy and reduce adverse drug reactions and toxicity for drugs metabolized by CYP enzymes.
在全球范围内,普通人群中的细胞色素 P450(CYP)介导的药物代谢存在显著的个体间和个体内差异。遗传多态性是个体间差异的主要贡献因素之一,但表观遗传机制主要导致个体内差异,包括 DNA 甲基化、组蛋白修饰、microRNAs 和长非编码 RNA。本综述分析了过去十年中关于表观遗传机制对 CYP 介导的药物代谢个体内差异的贡献的最新知识,包括:(1)个体从新生儿到成年的 CYP 表达的发育变化;(2)药物治疗诱导的 CYP 酶活性增加;(3)新生儿时期药物治疗诱导的成年时期 CYP 酶活性增加;(4)药物性肝损伤(DILI)个体中 CYP 酶活性降低。此外,还讨论了 CYP 药物基因组表观遗传学发展中的当前挑战、知识空白和未来展望。总之,表观遗传机制已被证明可导致 CYP 酶介导的药物代谢在年龄发育、药物诱导和 DILI 条件下的个体内差异。这一知识有助于理解个体内差异是如何产生的。未来的研究需要开发基于 CYP 的药物基因组表观遗传学,以指导精准医学的临床应用,提高治疗效果,降低不良反应和毒性的风险。
了解 CYP 介导的药物代谢个体内差异的表观遗传机制可能有助于开发基于 CYP 的药物基因组表观遗传学,以指导精准医学的临床应用,提高治疗效果,降低 CYP 酶代谢药物的不良反应和毒性。